Keros Therapeutics's total assets for Q2 2025 were $757.16M, a decrease of -3.49% from the previous quarter. KROS total liabilities were $50.43M for the fiscal quarter, a -9.44% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.